Large-Scale Synthesis of Piperazine-2,6-dione and Its Use in the Synthesis of Dexrazoxane Analogues

Abstract

An efficient, large-scale synthesis of piperazine-2,6-dione was developed. The advantages of this procedure include the use of inexpensive starting materials, satisfactory yields, and a convenient workup without the need for chromatographic techniques. Furthermore, this procedure can be easily modified for the preparation of 1-substituted piperazine-2,6-dione hydrobromides. The utility of the prepared piperazine-2,6-dione was demonstrated in the synthesis of a novel analogue of the only drug used in clinical practice to prevent anthracycline-induced cardiotoxicity, dexrazoxane.

Key words

piperazine-2,6-dione - large-scale synthesis - dexrazoxane - cyclization - synthesis - formamide

• References

• 1 Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. J. Clin. Oncol. 2008; 26: 3777
• 2 Jirkovsky E, Lencova-Popelova O, Hroch M, Adamcova M, Mazurova Y, Vavrova J, Micuda S, Simunek T, Gersl V, Sterba M. Toxicology 2013; 311: 191
• 3 Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Pharmacol. Rep. 2009; 61: 154
• 4 Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T. Antioxid. Redox Signal. 2013; 18: 899
• 5 Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Curr. Med. Chem. 1998; 5: 1
• 6 Classen S, Olland S, Berger JM. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 10629
• 7 Zhang S, Liu X, Bawa-Khalfe T, Lu L.-S, Lyu YL, Liu LF, Yeh ET. H. Nat. Med. 2012; 18: 1639
• 8 Herman EH, Elhage AN, Creighton AM, Witiak DT, Ferrans VJ. Res. Commun. Mol. Pathol. Pharmacol. 1985; 48: 39
• 9 Herman EH, Zhang J, Hasinoff BB, Chadwick DP, Clark JR, Ferrans VJ. Cancer Chemother. Pharmacol. 1997; 40: 400
• 10 Jirkovska-Vavrova A, Roh J, Lencova-Popelova O, Jirkovsky E, Hruskova K, Potuckova-Mackova E, Jansova H, Haskova P, Martinkova P, Eisner T, Kratochvil M, Sus J, Machacek M, Vostatkova-Tichotova L, Gersl V, Kalinowski DS, Muller MT, Richardson DR, Vavrova K, Sterba M, Simunek T. Toxicol. Res. (Cambridge, U. K.) 2015; 4: 1098
• 11 Prevention and treatment of cardiac conditions: Cross MR, Dilly SG, Scaife M. US2008/275036, 2008
• 12 Bis diketopiperazines: Creighton AM. US3941790, 1976
• 13 Barot NR, Elvidge JA. J. Chem. Soc., Perkin Trans. 1 1972; 1009
• 14 Mancilla T, Carrillo L, Zamudio-Rivera LS, Beltran HI, Farfan N. Org. Prep. Proced. Int. 2002; 34: 87
• 15 Hou X, Ge Z, Wang T, Guo W, Wu J, Cui J, Lai C, Li R. Arch. Pharm. 2011; 344: 320
• 16 Shvedaite IP. Chem. Heterocycl. Compd. 1995; 31: 63
• 17 Dinsmore CJ, Beshore DC. Tetrahedron 2002; 58: 3297
• 18 Čapek K, Čapková J, Jarý J, Trška P. Collect. Czech. Chem. Commun. 1984; 49: 1914
• 19 Cignarella G, Nathanson G. J. Org. Chem. 1961; 26: 1500
• 20 Henry DW. J. Heterocycl. Chem. 1966; 3: 503
• 21 Gregory H, Morley JS, Smith JM, Smithers MJ. J. Chem. Soc. C 1968; 715
• 22 Snapka RM, Woo SH, Blokhin AV, Witiak DT. Biochem. Pharmacol. 1996; 52: 543
• 23 Pham TQ, Pyne SG, Skelton BW, White AH. Tetrahedron Lett. 2002; 43: 5953
• 24 Hennessy EJ, Buchwald SL. J. Org. Chem. 2005; 70: 7371
• 25 Kronenthal DR, Han CY, Taylor MK. J. Org. Chem. 1982; 47: 2765
• 26 Yamaura M, Suzuki T, Hashimoto H, Yoshimura J, Okamoto T, Shin C. Bull. Chem. Soc. Jpn. 1985; 58: 1413
• 27 Morris J, Wishka DG. J. Org. Chem. 1991; 56: 3549
• 28 Rigby JH, Gupta V. Synlett 1995; 547
• 29 Chida N, Ohtsuka M, Ogawa S. J. Org. Chem. 1993; 58: 4441
• 30 Brooke GM, Mohammed S, Whiting MC. Chem. Commun. 1997; 1511
• 31 Akiyama T, Takesue Y, Kumegawa M, Nishimoto H, Ozaki S. Bull. Chem. Soc. Jpn. 1991; 64: 2266
• 32 Abalain C, Langlois M. Eur. J. Med. Chem. 1998; 33: 155
• 33 Shvedaite IP. Chem. Heterocycl. Compd. 1998; 34: 1185